OssDsign reaches milestone of 100 patients in its PROPEL registry ahead of time
Uppsala, November 9, 2022. OssDsign AB (publ.) today announces that the company has reached the milestone of 100 patients in the multi-centre, prospective spinal fusion registry, PROPEL. The registry was initiated in March 2022, to gather real-world data from patients who have been treated with OssDsign Catalyst.During 2022, clinics have gradually enrolled patients to the PROPEL registry, with the objective to evaluate the use and outcome of OssDsign Catalyst in a real-world clinical practice. The primary endpoint of the study is measuring the rate of spinal fusion, using computer